8-K: Twist Bioscience Reports Record Revenue in Fiscal Q1 2025, Gross Margin Improves

Twist Bioscience achieved record revenue of $88.7 million in the first quarter of fiscal year 2025, marking an increase of 24% year-over-year and the eighth consecutive quarter of sequential growth.

Summary

• Twist Bioscience reported a record revenue of $88.7 million for the first quarter of fiscal year 2025, a 24% increase compared to $71.5 million in the same period last year.
• The company's gross margin improved to 48.3% in Q1 FY25, up from 40.5% in Q1 FY24.
• SynBio revenue grew by 28% to $34.4 million, NGS revenue increased by 23% to $48.6 million, and Biopharma revenue reached $5.7 million.
• The net loss for the quarter was $31.6 million, or $0.53 per share, an improvement from a net loss of $43.0 million, or $0.75 per share, in the same quarter of the previous year.
• Adjusted EBITDA for the quarter was $(16.3) million, compared to $(27.8) million in the first quarter of fiscal 2024.
• Twist shipped products to approximately 2,376 customers and approximately 205,000 genes during the quarter.
• The company expects full-year fiscal 2025 revenue to be between $372 million and $379 million, with a gross margin projected to be approximately 49% and over 50% for 4QFY25.
• Adjusted EBITDA for fiscal 2025 is expected to be between $(55) million and $(60) million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross margins, and a reduction in net loss. The company is making progress towards profitability, and the future outlook is optimistic. However, the company is still operating at a loss.

Positives

• The company achieved its eighth consecutive quarter of revenue growth.
• Gross margin showed a significant improvement, increasing by 7.8 percentage points year-over-year.
• The company's net loss decreased substantially compared to the same period last year.
• Adjusted EBITDA improved, indicating progress towards breakeven.
• The company increased the number of customers served and genes shipped.
• Full-year revenue guidance was increased slightly, and gross margin guidance was also increased.

Negatives

• The company still reported a net loss of $31.6 million for the quarter.
• The company is still operating at a loss with an adjusted EBITDA of $(16.3) million for the quarter.
• Selling, general and administrative expenses increased to $56.2 million from $52.8 million in the same period last year.

Risks

• The company's future performance is subject to market conditions and other factors.
• The company faces risks related to rapidly changing technologies and competition in the synthetic biology sector.
• The company's ability to achieve profitability depends on its ability to attract new customers and retain existing ones.
• The company's dependence on a single supplier for a critical component poses a risk.
• The company's ability to maintain and enforce intellectual property protection is crucial.

Future Outlook

Twist expects full-year fiscal 2025 revenue to be between $372 million and $379 million, with a gross margin of approximately 49% and over 50% for 4QFY25. Adjusted EBITDA for fiscal 2025 is expected to be between $(55) million and $(60) million. The company also expects sequential improvements in adjusted EBITDA throughout 2025.

Management Comments

• We ended the first quarter of fiscal 2025 with our eighth consecutive quarter of revenue growth and continued improvement in gross margin.
• We're starting the fiscal year strong, demonstrating our unwavering commitment to progressing toward adjusted EBITDA breakeven.
• As we move through 2025, we are pursuing multiple growth vectors that we believe will help us to achieve adjusted EBITDA breakeven and then build on our foundation to drive sustainable growth in the years to come.
• Importantly, we expect to exit the fourth quarter of fiscal 2025 with gross margin over 50%.

Industry Context

Twist Bioscience operates in the rapidly growing synthetic biology and genomics sector. The company's focus on DNA synthesis and its applications in various industries positions it to benefit from the increasing demand for these technologies. The results indicate a strong growth trajectory in a competitive market.

Comparison to Industry Standards

• Twist's revenue growth of 24% year-over-year is strong compared to other companies in the synthetic biology space, such as Ginkgo Bioworks, which has seen more variable growth rates.
• The improvement in gross margin to 48.3% is a positive sign, as many companies in this sector struggle with profitability. Companies like Codexis have also been focused on improving gross margins.
• The adjusted EBITDA of $(16.3) million is an improvement, but the company still needs to achieve breakeven, which is a common challenge for growth-stage biotech companies. Companies like Amyris have faced similar challenges in achieving profitability.
• Twist's focus on multiple growth vectors, including SynBio, NGS, and Biopharma, is a strategy similar to that of other diversified biotech companies like Illumina, which also operates in multiple segments of the genomics market.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and improved financial metrics.
• Employees may be encouraged by the company's progress and positive outlook.
• Customers will benefit from the company's continued innovation and product development.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company plans to continue pursuing multiple growth vectors to achieve adjusted EBITDA breakeven.
• The company will focus on improving gross margin, aiming to exceed 50% by the end of fiscal year 2025.
• The company will hold a conference call to discuss the results and provide an update on the business.

Key Dates

Keywords

Twist Bioscience, Synthetic Biology, Genomics, DNA Synthesis, NGS, SynBio, Biopharma, Revenue, Gross Margin, EBITDA, Financial Results